Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Ibrolipim
Cat. No.:
OB0425LY-055
Appearance:
Solid
Purity:
99.3%
Identity:
Confirmed by NMR and LC-MS.
Size:
Add to basket
Product Overview
Description:
Ibrolipim is an active lipoprotein lipase (LPL)-promoting agent with renoprotective and hypolipidemic effects.
Synonyms:
133208-93-2; NO-1886; 4-Diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide; Phosphonic acid, [[4-[[(4-bromo-2-cyanophenyl)amino]carbonyl]phenyl]methyl]-, diethyl ester
CAS No.:
133208-93-2
Compound CID:
131601
Formula:
C19H20BrN2O4P
Formula Weight:
451.25
Specification
Target:
Lipase
Pathway:
Metabolic enzyme/Protease
Solubility:
DMSO
Storage:
Storage at -20°C.
Applications:
Ibrolipim can be used in kidney disease, hyperlipidemia and obesity studies.
